MD Anderson Cancer Center has established the Texas Health Equity Alliance for Breast Cancer (THEAL), a community-wide health care initiative to reduce breast cancer disparities in the Houston area, particularly for Black women.
Further positive results from the phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor—palbociclib, ribociclib or abemaciclib—maintained its progression-free survival benefit with longer follow-up and delivered a statistically significant and clinically meaningful improvement in second progression-free survival, demonstrating sustained benefit beyond initial treatment.
